Slc - thanks for the links and highlight on Malaria
I completely agree on Malaria as focus area - i am also interested on Autism compound KM-391 - in terms revenue stream Autism is much bigger
The problem I see is all these possible compounds are too much to bite for a small company as CTIX that has very limited resources, no partner and no visibility
So we need to uplist - start ph 3 for B and then change focus to the pipeline - IMO
Great data! The article on PYMX's antimalarial products is exciting. What an event...the "Polyheist"...the gift that will keep on giving. Thanks for your constant research!